DMRA DMRA
Company Profile ↓Company Overview
DMRA (DMRA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 7.8.
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +810.78% |
| 6 Months: | +20.38% |
| 3 Months: | +23.96% |
| 1 Month: | +2.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 4.83M | -5.83M | -6.34M | -10.17M | -13.55M | -12.27M | -12.94M | -16.94M | -17.12M | -13.62M | -13.49M | -11.16M | -8.58M | -5.74M | -5.58M | -3.84M | -2.60M | -3.42M | -3.16M | -30.81M |
| Net Income | -4.11M | -5.67M | -5.93M | -11.65M | -13.35M | -12.30M | -12.70M | -16.94M | -16.89M | -13.73M | -12.99M | -10.74M | -8.14M | -5.48M | -5.34M | -3.88M | -2.53M | -3.44M | -3.13M | -27.78M |
| Diluted EPS | - | - | - | - | - | - | -0.50 | -0.67 | -0.67 | -0.54 | -0.51 | -0.41 | -7.50 | -5.05 | -4.92 | -3.39 | -1.92 | -2.60 | -2.36 | -0.62 |
| R&D Expense | 3.67M | 4.71M | 4.51M | 7.65M | 9.99M | 8.63M | 9.75M | 13.23M | 13.71M | 10.49M | 10.36M | 8.09M | 2.55M | 2.46M | 1.83M | 1.09M | 678.00K | 1.47M | 1.42M | 23.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Income | 38.97M | -33.64M | -52.23M | -61.21M | -39.91M | -22.26M | -210.87M |
| Net Income | -36.51M | -34.84M | -51.75M | -61.62M | -38.35M | -21.44M | -209.84M |
| Diluted EPS | - | - | -2.05 | -2.43 | -36.08 | -18.53 | 3.98 |
| R&D Expense | 19.74M | 24.63M | 38.49M | 48.21M | 23.77M | 6.40M | 26.88M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 56.61M | 171.60M | 122.22M | 73.19M | 38.23M | 17.13M | 260.53M |
| Total Equity | -33.84M | -71.15M | 165.49M | 117.22M | 61.75M | 32.33M | 15.83M | 240.38M |
| Cash & Equivalents | - | 11.29M | 163.58M | 62.56M | 32.79M | 21.46M | 14.18M | 257.62M |
| Total Liabilities | - | 8.14M | 6.11M | 4.99M | 11.44M | 5.90M | 1.30M | 20.15M |
| Current Liabilities | - | 7.93M | 5.57M | 4.54M | 11.11M | 5.83M | 1.20M | 20.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.33M | -38.20M | - | -42.93M | -36.91M | -18.62M | -6.73M |
| Investing Cash Flow | -326.00K | - | - | 12.38M | 22.33M | 11.65M | -17.37M |
| Financing Cash Flow | - | 187.39M | - | 507.00K | 2.88M | 0 | 266.84M |
| Capital Expenditure | - | - | -223.00K | -196.00K | - | - | - |
| Free Cash Flow | - | - | - | -43.13M | -36.91M | -18.62M | -6.73M |
| Net Change in Cash | - | - | - | -30.04M | -11.71M | -6.97M | 242.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 51.3% | -21.1% | -44.1% | -99.8% | -118.6% | -135.4% | -87.3% |
| ROCE % | 80.1% | -20.3% | -44.4% | -98.6% | -123.2% | -139.7% | -87.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DMRA
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-…
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards t…
Damora Announces Redomestication from Delaware to Cayman Islands
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of …
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clin…
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
Damora Therapeutics recently overhauled its leadership team, appointing Jennifer Jarrett as President and CEO and naming Brian Burkavage as principal financial and accounting officer following the planned departure of CFO Lori Firmani effec…
DMRA — Frequently Asked Questions
What is the current share price of DMRA?
As of 2026-08-05 17:25 PDT, DMRA trades at $30.83 on NASDAQ/NYSE. Its 52-week range is $2.58 to $34.14.
What is the P/E ratio of DMRA?
DMRA trades at a trailing price-to-earnings (P/E) ratio of 7.75.
What is the return on equity (ROE) of DMRA?
DMRA has a return on equity (ROE) of -87.29%. Its return on capital employed (ROCE) is -87.69%.
Is DMRA a good stock to buy?
This page provides a data-driven analysis of DMRA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.